These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 35460294)
21. Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection. Bea S; Lee H; Park S; Cho YM; Choi WS; Bykov K; Shin JY Clin Pharmacol Ther; 2024 May; 115(5):1132-1140. PubMed ID: 38284421 [TBL] [Abstract][Full Text] [Related]
22. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213 [TBL] [Abstract][Full Text] [Related]
23. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Jung C; Park S; Kim H PLoS One; 2023; 18(11):e0294423. PubMed ID: 37992029 [TBL] [Abstract][Full Text] [Related]
24. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis. Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696 [TBL] [Abstract][Full Text] [Related]
25. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Kawalec P; Mikrut A; Łopuch S Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965 [TBL] [Abstract][Full Text] [Related]
26. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074 [TBL] [Abstract][Full Text] [Related]
27. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study. Shin A; Koo BK; Lee JY; Kang EH BMJ; 2024 Aug; 386():e079475. PubMed ID: 39197881 [TBL] [Abstract][Full Text] [Related]
28. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study. Yang CT; Yang CY; Ou HT; Kuo S Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570 [TBL] [Abstract][Full Text] [Related]
29. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303 [TBL] [Abstract][Full Text] [Related]
30. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis. Yang S; He W; Zhao L; Mi Y PLoS One; 2022; 17(4):e0267025. PubMed ID: 35421174 [TBL] [Abstract][Full Text] [Related]
31. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists. Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715 [No Abstract] [Full Text] [Related]
32. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014 [TBL] [Abstract][Full Text] [Related]
33. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402 [TBL] [Abstract][Full Text] [Related]
34. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study. Sung HL; Hung CY; Tung YC; Lin CC; Tsai TH; Huang KH Diabetes Metab Res Rev; 2024 Mar; 40(3):e3784. PubMed ID: 38402457 [TBL] [Abstract][Full Text] [Related]
35. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336 [TBL] [Abstract][Full Text] [Related]
36. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543 [TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease. Rhee JJ; Han J; Montez-Rath ME; Chertow GM Diabetes Obes Metab; 2024 Apr; 26(4):1273-1281. PubMed ID: 38186297 [TBL] [Abstract][Full Text] [Related]
38. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. Douros A; Lix LM; Fralick M; Dell'Aniello S; Shah BR; Ronksley PE; Tremblay É; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ernst P; Filion KB; Ann Intern Med; 2020 Sep; 173(6):417-425. PubMed ID: 32716707 [TBL] [Abstract][Full Text] [Related]
39. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases. Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746 [TBL] [Abstract][Full Text] [Related]
40. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes. Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR Sci Rep; 2018 Oct; 8(1):15142. PubMed ID: 30310100 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]